Skip to main content
PMC home page
Annals of Oncology logoLink to Annals of Oncology
. 2018 May 5;30(2):344. doi: 10.1093/annonc/mdx823

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

P Schöffski, A Wozniak, S Stacchiotti, P Rutkowski, J -Y Blay, L H Lindner, S J Strauss, A Anthoney, F Duffaud, S Richter, V Grünwald, M G Leahy, P Reichardt, J Sufliarsky, W T van der Graaf, R Sciot, M Debiec-Rychter, T van Cann, S Marréaud, M Lia, T Raveloarivahy, L Collette, S Bauer
PMCID: PMC6386024  PMID: 29741569

Ann Oncol 2017; 28: 3000–3008 (doi: 10.1093/annonc/mdx527)

In the original version, one of the authors of the above article was listed incorrectly as ‘Paolo Casali’ rather than ‘Silvia Stacchiotti’. This has now been corrected.

Articles from Annals of Oncology are provided here courtesy of Oxford University Press

RESOURCES